2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, Neutropenia, Infectious Diseases, Viral, Bacterial, Fungal, Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

6218 Clinical profile and comorbidity burden among adults in the United States with hereditary hemochromatosis: A Real-world cohort study

Gbenga A Kayode, MD, PhD, Sonya Abraham, MD, PhD2, Neloufar Rahai3, Charlotte Pollet, MSc4, Daniela Benitez5, Elizabeth Dabrowski6, Gregory J. Kato, MD7
1 CSL Behring, King of Prussia, Pennsylvania, United States
2 CSL Behring, King of Prussia, Pennsylvania, United States
3 2222 West Dunlap Avenue, Phoenix, Arizona, United States
4 CSL Behring, King of Prussia, Pennsylvania, United States
5 2222 West Dunlap Avenue, Phoenix, Arizona, United States
6 2222 West Dunlap Avenue, Phoenix, Arizona, United States
7 CSL Behring, King of Prussia, Pennsylvania, United States

Background: Hereditary hemochromatosis (HH) is a genetic disorder characterized by excessive iron absorption and accumulation that can lead to organ damage such as liver dysfunction, cardiomyopathy, heart failure, endocrine, and pancreatic disease. Phlebotomy is considered the standard treatment, however, despite its widespread use, there is limited evidence that phlebotomy adequately addresses HH-related symptoms or improves quality of life. Few published studies exist that characterize the clinical profile and comorbidity burden among patients with HH, particularly those with insufficient response to phlebotomy. Understanding these patient profiles has important implications for improving disease management and targeting therapeutic strategies for patients living with HH.

 

Methods: A retrospective cohort study using data from the TriNetX Linked Network, a US dataset linking electronic health records and medical and pharmaceutical claims for approximately 12 million patients, was conducted. Adult patients with HH, defined in this study as either two ICD-10 diagnosis codes for HH on separate days or one diagnosis code for HH with evidence of therapeutic phlebotomy at any time, between January 1, 2014, and December 31, 2019, were included, while patients requiring phlebotomy for non-HH indications or with hematologic conditions associated with transfusion-related iron overload were excluded. Follow-up began on the date of the first observable HH diagnosis in the study period (index date) and continued for up to ten years post-index. Clinical and non-clinical characteristics, assessed in baseline and follow-up periods separately, were described overall and in subgroups defined by treatment response status at index (insufficient response or intolerance of phlebotomy [defined as a serum ferritin ≥100 ng/mL in patients with inadequate or no phlebotomy treatment], high-burden phlebotomy [defined as ≥3 treatments per person-month in the induction phase or ≥4 treatments per person-year in the maintenance phase], incident HH) and average serum ferritin level (<50, 50–<100, 100–<300, ≥300 ng/mL).

 

Results: Of the 16,711 patients with HH in the TriNetX dataset, 6,234 met study eligibility criteria; among those 541 (9%) had insufficient response or intolerance of phlebotomy at index, 10 had high-burden phlebotomy at index, and 2,087 indexed on an incident diagnosis. Among patients with available serum ferritin data, most had an average level of 100 to <300 ng/mL (n = 690) and ≥300 ng/mL (n = 506) over the baseline and follow-up periods. Mean age was approximately 52 years overall and 58 years among those with high-burden phlebotomy at index, and nearly two-thirds of HH patients overall were male (62%). Comorbidity burden and healthcare utilization were highest among the small subset of patients (n = 10) who had high-burden phlebotomy at index, as well as among those with an average serum ferritin level of ≥300 ng/mL during the baseline and follow-up periods. Patients with insufficient response or intolerance of phlebotomy at index had higher rates of heart failure, chronic kidney disease, cirrhosis, fibromyalgia, chronic inflammatory disease, autoimmune disease, anxiety, depression, cognitive/memory conditions, hypothyroidism, and diabetes compared to the overall study population. Among patients with lower serum ferritin levels (<300 ng/mL), most had a Charlson Comorbidity Index (CCI) score of 0 - 2, and the proportions of most comorbidities were lower compared with the subgroup of patients whose average serum ferritin was ≥300 ng/mL, which aligned with the most cardiovascular and hematologic burden.

 

Conclusions: Findings from this real-world cohort of US adults with HH characterize subgroups of patients with high phlebotomy burden, no response to phlebotomy, and elevated comorbidity burden across psychological, endocrine, cardiovascular, and hematologic conditions, representing a population with unmet therapeutic need. Comorbidity burden was highest among prevalent cases, patients with insufficient response or intolerance of phlebotomy, and those with persistently elevated ferritin levels, suggesting that complications due to iron overload are not well-controlled under current standard-of-care practices. These findings highlight the value of real-world evidence in informing disease understanding and targeting therapeutic development for patients living with HH, in particular those not adequately managed with phlebotomy.

Gregory J. Kato, MD: CSL - Current equity holder in private company; CSL - Current Employment